losartan has been researched along with glimepiride in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Harakawa, N; Hasegawa, R; Kamide, K; Kaniwa, N; Katori, N; Kim, SR; Maekawa, K; Miyata, T; Saito, Y; Sawada, J; Sugiyama, E; Tohkin, M; Yasuda, K | 1 |
| Cai, J; Cai, JP; Chen, SZ; Dai, DP; Geng, PW; Hu, GX; Pan, PP; Shen, LB; Xu, SS | 1 |
| Chen, SZ; Hu, GX; Luo, J; Pan, PP; Wang, SH; Xu, SS; Yu, YF; Zhang, L | 1 |
1 review(s) available for losartan and glimepiride
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for losartan and glimepiride
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.
Topics: Alleles; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cytochrome P-450 Enzyme System; Diclofenac; DNA, Complementary; Genetic Variation; Humans; Hypoglycemic Agents; Insecta; Japan; Kinetics; Losartan; Microsomes; Rats; Recombinant Proteins; Substrate Specificity; Sulfonylurea Compounds | 2009 |
Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
Topics: Angiotensin II Type 1 Receptor Blockers; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C9; Drug Interactions; Humans; Hydroxylation; Hypoglycemic Agents; Kinetics; Losartan; Microsomes; Oxidation-Reduction; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Recombinant Proteins; Risk Assessment; Risk Factors; Sulfonylurea Compounds | 2014 |
In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism.
Topics: Animals; Antihypertensive Agents; Cytochrome P-450 Enzyme System; Drug Interactions; Hypoglycemic Agents; Losartan; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds | 2015 |